Document series
Trial abstracts — page 21
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 21 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| AWARD-5-OLEprogramme record | Dulaglutide | Phase 3 | Reported | Single-arm open-label | — | 2014 | Very low |
| AWARD-5-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| AWARD-6-ADHERENCEprogramme record | Dulaglutide | Phase 3 | Reported | Observational | — | 2014 | Very low |
| AWARD-6-BIOMARKERprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| AWARD-6-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| AWARD-6-ELDERLYprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| AWARD-6-OLEprogramme record | Dulaglutide | Phase 3 | Reported | Single-arm open-label | — | 2014 | Very low |
| KISS-IVF-TRIGGER-DDIprogramme record | Kisspeptin-10 | Phase 1 | Reported | Randomised crossover | — | 2014 | Very low |
| KISS-IVF-TRIGGER-HEPATIC-IMPprogramme record | Kisspeptin-10 | Phase 1 | Reported | Phase 1 ascending dose | — | 2014 | Very low |
| KISS-IVF-TRIGGER-PKprogramme record | Kisspeptin-10 | Phase 1 | Reported | Phase 1 ascending dose | — | 2014 | Very low |
| KISS-IVF-TRIGGER-RENAL-IMPprogramme record | Kisspeptin-10 | Phase 1 | Reported | Phase 1 ascending dose | — | 2014 | Very low |
| LL37-PH1-2-VENOUSULCER-BODY-COMPprogramme record | LL-37 | Phase 1/2 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| LL37-PH1-2-VENOUSULCER-QOLprogramme record | LL-37 | Phase 1/2 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| LL37-PH1-2-VENOUSULCER-REGIONAL-CNprogramme record | LL-37 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| LL37-PH1-2-VENOUSULCER-REGIONAL-JPprogramme record | LL-37 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2014 | Very low |
| DURATION-6-ADHERENCEprogramme record | Exenatide | Phase 3 | Reported | Observational | — | 2013 | Very low |
| DURATION-6-BIOMARKERprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| DURATION-6-ELDERLYprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| DURATION-6-OLEprogramme record | Exenatide | Phase 3 | Reported | Single-arm open-label | — | 2013 | Very low |
| DURATION-6-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| GETGOAL-DUO-1-DDIprogramme record | Lixisenatide | Phase 1 | Reported | Randomised crossover | — | 2013 | Very low |
| GETGOAL-DUO-1-ELDERLYprogramme record | Lixisenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| GETGOAL-DUO-1-HEPATIC-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2013 | Very low |
| GETGOAL-DUO-1-PKprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2013 | Very low |
page 21 of 30